Antibiotic prophylaxis in surgery (ADULTS) Type of Surgery Antibiotic of Choice Alternative in true Penicillin Allergy or MRSA carriage
|
|
- Jasmine Anabel Chandler
- 6 years ago
- Views:
Transcription
1 These guidelines have been amended to reduce the incidence of Clostridium difficile associated diarrhoea and includes recommendations from the most recent guidance 1-8 NB. If patient is a VRE carrier or has had a recent VRE infection, please contact a Microbiologist for advice as standard antibiotics will be ineffective. Important notes: Refer to British National Formulary for further details of cautions, contra-indications, side effects and dosages 1. The pre-operative antimicrobial dose should be administered within 30 minutes before skin incision. However, give prophylaxis earlier for operations in which a tourniquet is used 2. An additional dose of antibiotic prophylaxis may be given during operations 1,2 a. lasting more than 4 hours b. in the event of major intra-operative blood loss (>1500ml). additional dosage of prophylactic antibiotics should be consider after fluid replacement 3. Antibiotic prophylaxis should be confined to the perioperative period only Postoperative doses should not be given, unless stated in the guidance or agreed with Microbiology 4. When severe renal impairment known or suspected please contact Pharmacy or Microbiology department for advice 5. If history of life threatening allergy to penicillin (e.g. anaphylaxis, angioedema, facial/throat swelling), consult microbiology/pharmacy for advice 6. Avoid cephalosporins (cefuroxime) in all patients 7. Alternative antibiotics should only be given if the patient has a penicillin allergy or is colonised or infected with MRSA 8. Where prophylaxis is not given when recommended, should be clearly recorded in the case records 9. With gentamicin, the risk of ototoxicity may be increased by other ototoxic drugs, e.g. furosemide. The risk of nephrotoxicity is increased by other drugs e.g. NSAIDs, cephalosporins, vancomycin and amphotericin. 7 Gentamicin key points 10. Gentamicin doses over 240 mg should be given as a 30 to 60 min infusion 11. Gentamicin Intravenous bolus injection should be given over 3 minutes Gentamicin- Maximum dose of 500mg OD 13. Gentamicin may interact with neuromuscular blocking agents e.g. suxamethonium used during anaesthesia, and can enhance the potential neuromuscular blockade 7 Orthopaedic surgery Total hip replacement Prosthetic knee joint Replacement (regardless of use of antibiotic cement) Hip fracture repair Spinal surgery Insertion of prosthetic Device Revision arthroplasty Major trauma/open fractures Co-amoxiclav 1.2 g IV at, followed by a second dose 8 hours later, and a final dose 8 hours later (total of 3 doses in 24 hours) Single dose Co-amoxiclav 1.2 g IV at Can be used for the following: Platings, metalwork insertion, metalwork removal, joint injections Antibiotics should NOT be given until samples have been taken Single dose Teicoplanin 10mg/kg IV (to nearest 100mg, maximum 800mg) stat after sampling + Meropenem 500mg IV stat bolus after sampling If sepsis syndrome followed by: Teicoplanin 10mg/kg IV (to nearest 100mg, maximum 800mg) 12 hourly for 3 doses then OD + Meropenem 500mg TDS IV Stop meropenem after 48 hours if no Gramnegatives on cultures and continue with teicoplanin until final cultures available, then seek advice from Microbiology Co-amoxiclav 1.2 g IV at, followed by a second dose 8 hours later, and a final dose 8 hours later (total of 3 doses in 24 hours) If Grossly contaminated add in: Metronidazole 500mg IV 8 hourly (2 doses) + Gentamicin 1.5mg/kg IV stat bolus at Consider extending treatment until definitive surgical procedure performed 800mg) stat at + Gentamicin 1.5mg/kg IV stat bolus at 800mg) 12 hours after first dose (two doses in total) Antibiotics should NOT be given until samples have been taken Single dose 800mg) stat after sampling + Gentamicin 1.5mg/kg IV stat bolus at If sepsis syndrome followed by: 800mg) 12 hourly for 3 doses then OD + Gentamicin 5mg/kg* IV as 30 to 60min infusion OD from day 2 onwards Gentamicin and Teicoplanin levels ARE required 800mg) stat at + Gentamicin 1.5mg/kg IV stat bolus at + Metronidazole 500mg IV stat at 800mg) 12 hours after first dose (two doses in total) + Metronidazole 500mg IV 8 hourly (2 doses) Consider extending treatment until definitive surgical procedure performed (additional gentamicin from day 2 onwards required. Gentamicin levels ARE required) Orthopaedic surgery without prosthetic device (elective) * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). ; 1 of 6
2 Obstetrics and Gynaecology Caesarean section Hysterectomy (abdominal or vaginal) Perineal tear third or fourth degree involving anal sphincter/rectal mucosa Manual removal of placenta Co-amoxiclav 1.2g i.v. stat at 9 During a caesarean section, prophylaxis could be delayed until the cord is clamped (at + Metronidazole 500mg i.v. stat Surgical termination of pregnancy Co-amoxiclav 1.2g i.v. stat at Plus Azithromycin 1gram PO if patient not screened for STDs prior to the procedure If PID suspected, please refer to the Trust Antibiotic Guidance or contact Microbiology or Sexual Health Medicine for further advice Assisted delivery Evacuation of complete mis Urology Transrectal prostate biopsy +/- Metronidazole 500mg i.v. stat at (at Hydrocoeles/hernia repair Transurethral resection of the prostate Transurethral resection of bladder tumours At surgeon s discretion may consider Nephrectomy +/- Metronidazole 500mg i.v. stat at (at At surgeon s discretion may consider Cystoscopy To be considered if high risk of UTI Ciprofloxacin 500 mg p.o. 1 hour before procedure (single dose) 8 If urine colonised with resistant organism: or contact Microbiology for targeted therapy To be considered if high risk of UTI Ciprofloxacin 500 mg p.o. 1 hour before procedure (single dose) 8 If urine colonised with resistant organism: or contact Microbiology for targeted therapy * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Dosing is based on actual body weight (ABW) unless patient is obese (20% over ideal body weight-(ibw)) Obese dosing weight= IBW+ 0.4 (ABW-IBW). 2 of 6
3 UPPER GASTROINTESTINAL Oesophageal surgery Stomach and duodenal surgery Gastric bypass surgery Small intestine surgery Endoscopic gastrostomy LOWER GASTROINTESTINAL Colorectal surgery 4-5 Appendicectomy Suspected or confirmed Ruptured viscus/ peritoneal contamination HEPATOBILIARY Gentamicin 5mg/kg* i.v. infusion over 30 min at +/- Amoxicillin 1g i.v. stat at (at If Treatment regimen required (post surgery) Piperacillin/Tazobactam 4.5g i.v. 8 hourly for 5 to 7 days +/- Amoxicillin 1g i.v. stat at (at Piperacillin/Tazobactam 4.5g i.v. at Piperacillin/Tazobactam 4.5g i.v. 8 hourly for 5 to 7 days 60min at +/- Teicoplanin 400mg i.v. stat (at surgeon s If Treatment regimen required (post surgery) Metronidazole 500mg i.v. 8 hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD From day 2 add in: 60minutes OD Gentamicin and Teicoplanin levels ARE required +/- Teicoplanin 400mg i.v. stat (at surgeon s 60min at +/- Teicoplanin 400mg i.v. stat (at surgeon s If Treatment regimen required (post surgery) Metronidazole 500mg i.v. 8 hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD From day 2 add in: 60minutes OD Gentamicin and Teicoplanin levels ARE required Biliary surgery (open) Pancreatic surgery Liver surgery Gall bladder surgery (open) +/- Amoxicillin 1g i.v. stat at (at Gall bladder surgery (laparoscopic) +/- Teicoplanin 400mg i.v. stat at (at Gentamicin and Teicoplanin levels NOT required * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW+ 0.4 (ABW-IBW). 3 of 6
4 ABDOMEN Pseudomyxoma peritonei Laparoscopic or nonlaparoscopic hernia repair with mesh Co-amoxiclav 1.2 g i.v. at, followed by a second dose 4 hours later And a final dose 8 hours later (total of 3 doses in 24 hours) followed by: Metronidazole 500mg i.v. 8 hourly (total of 3 doses in 24hours) Gentamicin 3mg/kg i.v. infusion over 30 to 60min at, +/- Teicoplanin 400 mg i.v. stat at Metronidazole 500mg i.v. 8 hourly (2 doses) + Teicoplanin 400 mg i.v. one additional dose at 12 hours Gentamicin and Teicoplanin levels NOT required Laparoscopic or nonlaparoscopic hernia repair without mesh THERAPEUTIC ENDOSCOPIC PROCEDURES ERCP Endoscopic gastrostomy (PEG) + Amoxicillin 1g i.v. stat at (at + Teicoplanin 400mg i.v. stat at Gentamicin and Teicoplanin levels NOT required BREAST SURGERY Breast cancer surgery Breast reshaping procedures Breast surgery with implant (reconstructive or aesthetic) Breast cancer surgery with implant Flucloxacillin 2g i.v. stat at +/- Metronidazole 500mg i.v. stat at (at Flucloxacillin 2g i.v. stat at +/- Metronidazole 500mg i.v. stat at Flucloxacillin 1g i.v. 6hourly +Metronidazole 500mg i.v. 8hourly Until drains are removed Switch to oral antibiotics can be considered at 48 hours Teicoplanin 400mg i.v. stat at +/- Metronidazole 500mg i.v. stat at(at Teicoplanin level NOT required Teicoplanin 400mg i.v. stat at +/- Metronidazole 500mg i.v. stat (at surgeon s Metronidazole 500mg i.v. 8hourly + Teicoplanin 10mg/kg IV (to nearest 100mg: maximum 800mg) for 3 loading doses 12 hours apart then OD Until drains are removed Switch to oral antibiotics should be discussed with Microbiology Teicoplanin levels ARE required * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). 4 of 6
5 VASCULAR SURGERY Lower limb amputation Vascular surgery (abdominal & lower limb) Cardiothoracic Flucloxacillin 1g i.v. stat at + Gentamicin 240mg* i.v. stat at At surgeon s discretion may give up to 2 further doses of Flucloxacillin 500mg i.v. 6hourly + Metronidazole 500mg i.v. 8hourly (No further gentamicin) Teicoplanin 400mg i.v. stat at + + Metronidazole 500mg i.v. at At surgeon s discretion may give up to 2 further doses of Metronidazole 500mg i.v. 8hourly + Teicoplanin 400 mg i.v. one additional dose at 12 hours (No further gentamicin) Cardiac pacemaker insertion Flucloxacillin 1g i.v. stat at Teicoplanin 400mg i.v. stat at Head and neck surgery Head and neck surgery (contaminated & clean contaminated) Complex septorhinoplasty with implant Flucloxacillin 1g i.v. stat at Flucloxacillin 1g iv 6hourly (3 doses) + Metronidazole 500mg i.v. 8hourly (2 doses) Flucloxacillin 1g i.v. stat at Flucloxacillin 1g iv 6hourly (3 doses) + Metronidazole 500mg i.v. 8hourly (2 doses) Flucloxacillin 500 mg p.o. 6hourly for 5 days Head and neck surgery (clean) Clindamycin 900mg i.v. 8hourly (3 doses) Clarithromycin 500 mg i.v. 12hourly (2 doses) + Metronidazole 500mg i.v. 8hourly (3 doses) Clarithromycin 250 mg p.o. 12hourly for 5 days Ear surgery (clean) Ear surgery with Prosthesis Revision surgery Co-Amoxiclav 1.2g i.v. 8hourly (3 doses) Amoxicillin 500 mg p.o. 8hourly for 5 days Nose or sinus surgery Clarithromycin 500 mg i.v. 12hourly (2 doses) + Metronidazole 500mg i.v. 8hourly (3 doses) Clarithromycin 250 mg p.o. 12hourly for 5 days Tonsillectomy Grommet insertion Single dose of topical ofloxacin Single dose of topical ofloxacin * Patients with impaired renal function CrCl < 60 ml/min (Cockcroft-Gault) use a reduced dose of 3mg/kg Obese dosing weight= IBW (ABW-IBW). 5 of 6
6 References: 1 Scottish Intercollegiate Guidelines Network (SIGN) Antibiotic Prophylaxis in Surgery - Principles, 2008 available online at: 2 National Institute for Health and Clinical excellence (NICE) Surgical Site Infection Prevention and treatment of surgical site infection, October 2008 available on line at: 3 Privitera G, Scarpellini P, Ortisi G, Nicastro G, Nicolin R, de Lalla F. Prospective study of Clostridium difficile intestinal colonisation and disease following single dose antibiotic prophylaxis in surgery. Antimicrob Agents Chemother1991; 35: Health Technology Assessment (HTA) Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomised controlled trials, 1998 available on line at: 5 Zelenitsky S, Ariano R, Godfrey K, et al. Antibiotic Pharmacodynamics in Surgical Prophylaxis: and association between intraoperative antibiotic concentrations and efficacy. Antimicrob Agenst Chemother 2002; 46: Summary of Product Characteristics. Cidomycin adult injectable 80mg/2ml. (accessed 27 January 2009) 7 Wright J, Gray A, Goodey V. Clinical Pharmacy. Pharmaceutical Press Wolf J. S., Bennett C, Dmochowski R, et al. Best practice Policy Statement on Urology Surgery Antimicrobial Prophylaxis. American Urological Association. J. juro 2008; 179: of 6
Recommended Agent First alternative for β-lactam allergy Alternative Agents (in order of preference) document β-lactam allergy for SCIP)
Surgical Prophylaxis Guideline Updates Wadley Regional Medical Center Surgery and Trauma Committee, July 22, 2014 Pharmacy and Therapeutics Committee, August 2014 Compiled by: Andrea C Jarzyniecki, Pharm
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #21 (NQF 0268): Perioperative Care: Selection of Prophylactic Antibiotic First OR Second Generation Cephalosporin National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL
More informationDRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes
NHS ONEL & Barking, Havering & Redbridge University Hospitals Trust Shared Care Guidelines DRUG NAME : Clexane (enoxaparin) Pre-Filled Syringes DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED
More informationPerioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Perioperative management of patients on warfarin requiring elective surgery Dr K Boyd, Mrs S Doyle Haematology Acute Date Uploaded:
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationLovenox weight calculator
P ford residence southampton, ny Lovenox weight calculator What Are the Treatments for Hemangioma on the Liver? Sciatic Nerve Surgery Recovery Time. How to Determine the Best Brand of Compression Stockings
More informationVIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS
VIT-0910 STUDY: COUNTRY-SPECIFIC ADDENDUM FOR THE NETHERLANDS Investigational Medicinal Products 1. Paragraph 8.1: The protocol states that all drugs will need to be provided from commercial stock. However,
More informationEnoxaparin sodium 150mg (equivalent to 15,000 IU anti-xa. activity) in 0.2ml water for injections. activity) in 0.4ml water for injections
1. NAME OF THE MEDICINAL PRODUCT Clexane (Lovenox) Syringes Clexane (Lovenox) Forte Syringes 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clexane (Lovenox) Syringes (100mg/ml) 20mg Injection 40mg Injection
More informationGuideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
More informationPresenting SURGICEL Powder
SURGICEL Powder Presenting SURGICEL Powder Built to stop continuous, broad-surface oozing fast1,2 The next generation of SURGICEL Absorbable Hemostats SURGICEL Powder efficiently and effectively controls
More informationPublished 13 June 2011 Page May 2011
filgrastim, 30 million units (300 micrograms)/0.5ml, 48 million units (480 micrograms)/0.5ml, solution for injection or infusion in pre-filled syringe (Zarzio ) SMC No. (704/11) Sandoz Ltd 06 May 2011
More informationVerification of Disk Diffusion Tests
Verification of Disk Diffusion Tests Objectives 1. Describe disk diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification of
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationClinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.
NHS GREATER GLASGOW AND CLYDE BOWEL SCREENING PROGRAMME Clinical Policy Guidelines Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test. Date to
More informationReceived 26 February 1997/Returned for modification 16 September 1997/Accepted 10 February 1998
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 1998, p. 1093 1097 Vol. 42, No. 5 0066-4804/98/$04.00 0 Copyright 1998, American Society for Microbiology Comparison of Concentrations of -Ampicillin Administered
More informationBAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS AT AORN MEETING
FOR IMMEDIATE RELEASE Media Contact Beth Mueller, (224) 948-5353 media@baxter.com Investor Contact Clare Trachtman, (224) 948-3085 BAXTER UNVEILS DESIGN ENHANCEMENTS TO FLOSEAL AND TISSEEL HEMOSTATIC AGENTS
More informationVerification of Gradient Diffusion Strips
Verification of Gradient Diffusion Strips Objectives 1. Describe gradient diffusion tests 2. Describe process of FDA clearance of susceptibility tests 3. Discuss CLIA requirements for laboratory verification
More informationCoordinated Primary Options Service. DVT Management Plan. Management options using Dabigatran or Warfarin
Coordinated Primary Options Service DVT Management Plan Management options using Dabigatran or Warfarin Name NHI DOB Ethnicity Gender Address Contact Information Mobile Home Treatment commenced date *CPO
More informationEvaluateMedTech has used a number of sources within the site to develop a 4-level classification tree based on the FDA approvals process.
Classification of Approvals from Devices@FDA FDA Classification EvaluateMedTech has used a number of sources within the Devices@FDA site to develop a 4-level classification tree based on the FDA approvals
More informationReport on New Patented Drugs - Invanz
Report on New Patented Drugs - Invanz October 2006 Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB
More informationAutologous transfusion refers to those transfusions in which the blood
The SurgicalTechnologist JUE 2007 254 Intraoperative Autologous Blood Transfusion Margaret Sterling, cst, lpn, ma Autologous transfusion refers to those transfusions in which the blood donor and the transfusion
More informationMinimally Invasive Surgery
Minimally Invasive Surgery 1 RECOOP HST Research Activity Inventory Please complete the template for each selected project your organization would like to share with the partners of the RECOOP HST Consortium
More informationA comparison of CCSD and OPCS Procedure Classifications and an assessment of the mapping challenges.
White Paper Clinical Coding A comparison of CCSD and OPCS Procedure Classifications and an assessment of the mapping challenges. Peter Connor Managing Director Healthcode Ltd Frances Murphy ACC Clinical
More informationZINACEF GlaxoSmithKline
ZINACEF GlaxoSmithKline Cefuroxime sodium QUALITATIVE AND QUANTITATIVE COMPOSITION ZINACEF Injection contains 250 mg, 750 mg, 1 g and 1.5 g of cefuroxime (as cefuroxime sodium). ZINACEF MONOVIAL contains
More informationEPIMED: Can DRGs help to improve effectiveness, efficiency and safe use of drugs?
EPIMED: Can DRGs help to improve effectiveness, efficiency and safe use of drugs? Innovation and Information Technologies to improve Health Care Management Background High health care costs (growing) Pharmacological
More informationKinetics of galactomannan in surgical patients receiving perioperative piperacillin/tazobactam prophylaxis
Journal of Antimicrobial Chemotherapy Advance Access published August 30, 2006 Journal of Antimicrobial Chemotherapy doi:1093/jac/dkl334 Kinetics of galactomannan in surgical patients receiving perioperative
More informationPhysician Orders - Adult
Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy
More informationBoard in General Surgery Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons
Board General Surgery Royal Australasian College of s, General s Australia & New Zealand Association of General s SUMMARY OF OPERATIVE & NON-OPERATIVE TRAINING EXPERIENCE The required formation must be
More informationHuman pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
Journal of Antimicrobial Chemotherapy (2005) 55, Suppl. S2, ii25 ii30 doi:10.1093/jac/dki008 JAC Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide
More informationDenosumab for the prevention of skeletal related events in patients with multiple myeloma first line
NIHR Innovation Observatory Evidence Briefing: April 2017 Denosumab for the prevention of skeletal related events in patients with multiple myeloma first line NIHRIO (HSRIC) ID: 6619 NICE ID: 8815 LAY
More informationGlobal Endoscopy Market Report
Global Endoscopy Market Report ----------------------------------------- 2014 View Report Details Executive Summary Endoscopy is a minimally invasive diagnostic medical procedure in which a tube like instrument,
More informationContent on this page requires a newer version of Adobe Flash Player.
Content on this page requires a newer version of Adobe Flash Player. 13-1-2018 IV vesicants and pain while a vesicant will cause tissue damage if it escapes. Ciprofloxacin is not designated as a vesicant
More informationRevolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics
www.polymedix.com Revolutionizing the Treatment of Infectious Diseases with Defensin-Mimetics Ticker: PYMX March 2012 Disclaimer and Safe Harbor Forward-looking statements This presentation contains forward-looking
More informationJAC Surgical prophylaxis in Belgian hospitals: estimate of costs and potential savings
Journal of Antimicrobial Chemotherapy (1998) 41, 267 272 JAC Surgical prophylaxis in Belgian hospitals: estimate of costs and potential savings A. Sasse a, R. Mertens a *, J. P. Sion b, O. Ronveaux a,
More informationASERNIP-S. Australian Safety & Efficacy Register of New Interventional Procedures - Surgical. Royal Australasian College of Surgeons
ASERNIP-S Australian Safety & Efficacy Register of New Interventional Procedures - Surgical Member of International Network of Agencies for Health Technology Assessment Australia Population 23 million
More informationANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005
ANTICOAGULANT THERAPY REVISITED 2005 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most
More informationPLTW Biomedical Science Medical Interventions Course Outline
Follow the fictitious Smith family as you learn about the prevention, diagnosis, and treatment of disease. Play the role of biomedical professionals to analyze case information and diagnose and treat your
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
23 July 2015 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular
More informationTechnique of enteral nutrition
Life Long Learning Module 8.3 Technique of enteral nutrition Johann Ockenga, MD Dep.. of Gastroenterology, Hepatology & Endocrinology Universitätsmedizin tsmedizin Berlin Germany Copyright 2006 by ESPEN
More informationPress Release
Press Release www.shire.com This press release is intended for a global audience. Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric
More information10/2/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationAnti- THrombosis with Enoxaparin in intubated Adolescents
Anti- THrombosis with Enoxaparin in intubated Adolescents E. Vincent S. Faustino, MD, MHS October 2017 NHLBI submission S L I D E 0 Research question, central hypothesis and primary aim Research Question
More informationTAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS
HTC 11/02 TAYSIDE GUIDE TO MASSIVE TRANSFUSION/BLOOD LOSS This local guide should be used in conjunction with the guidelines published by the British Committee for Standards in Haematology. Definition:
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary
More informationRegulatory hurdles and opportunities
Regulatory hurdles and opportunities Professor Roger Finch Nottingham University Hospitals & University of Nottingham, UK Drug licensing and regulation Mandatory for market authorisation Supports the public
More informationA Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular
More informationGuidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients
Guidelines on Use of Haematopoietic Growth Factors in Adult Oncology and Haemato-oncology Patients The recombinant human granulocyte-colony stimulating factor (GCSF) of choice is Biosimilar filgrastim
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Forte Syringes 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Pre-filled syringes: 120 mg Injection Enoxaparin sodium 120 mg (equivalent
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationMEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationMDR ID: Definition: Applicable:
MDR Classification: (Reference Medical Device Regulation EU 2017/745, Annex VIII) Product: Product Name 1. DURATION OF USE MDR ID: Definition: Applicable: - Invasive Device: Continue Go to 2. Invasive
More informationOff Label or On Target? The Ethics of Investigational and Compassionate Uses
Off Label or On Target? The Ethics of Investigational and Compassionate Uses G. Kevin Donovan, MD, MA Director, Pellegrino Center for Clinical Bioethics Professor of Pediatrics Georgetown University School
More informationSoft Tissue Retaining Set
U.S. Toll Free 866-GOLIMBS Laparoscopic Surgery Soft Tissue Retaining Set Part No: 50151 For securing synthetic soft tissue components used in intermediate surgical training and laparoscopic trainers.
More informationBringing True Novelty to the Anti-Infective Space
Bringing True Novelty to the Anti-Infective Space New Class of Antibacterials Based on a Unique Mechanism of Action Dr Dawn Firmin SMi s 17 th Annual Conference on Superbugs & Superdrugs March 2015 1 Contents
More informationCombating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi
Combating Antibiotic Resistance: New Drugs 4 Bad Bugs (ND4BB) David Payne/Seamus O Brien for Astra Zeneca, Basilea, GlaxoSmithKline, J&J & Sanofi Need for public-private collaboration Challenges of AB
More information6/28/2016. Control of Microbial Growth. Method. Terminology. Disinfectants and Antiseptics
Control of Microbial Growth Disinfectants and Antiseptics 1 Method Three approaches for the control of microbial growth Chemical Disinfectants and antiseptics Physical Heat Ultraviolet Irradiations Mechanical
More informationSummary of Product Characteristics
Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Clexane Syringes 100mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg Injection 40mg Injection 60mg Injection
More informationDATA SHEET 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
DATA SHEET 1 CLEXANE AND CLEXANE FORTE * 2 QUALITATIVE AND QUANTITATIVE COMPOSITION CLEXANE Pre-filled syringes, ready-to-use: 20 mg injection enoxaparin sodium 20mg (equivalent to 2,000 IU anti-xa activity)
More informationThe Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital*
CHEST The Incidence of Recognized Heparin- Induced Thrombocytopenia in a Large, Tertiary Care Teaching Hospital* Maureen A. Smythe, PharmD, FCCP; John M. Koerber, PharmD; and Joan C. Mattson, MD Original
More informationLaminar flow in orthopaedic operations - Essential if you can afford it. Peter Hoffman Consultant Clinical Scientist Public Health England
Laminar flow in orthopaedic operations - Essential if you can afford it Peter Hoffman Consultant Clinical Scientist Public Health England Up until the 1950s in the UK (and elsewhere) Surgical instruments
More informationINTRODUCTION TO CLINICAL PHARMACY
CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 19 March 2009 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL
More informationWhat is an Investigational Drug? 21CFR312.3(b)
Review of the Investigational Drug and Device Regulations Changes to the RSRB Online Submission System (ROSS) Application for Drugs and Devices Kelley O'Donoghue Donoghue, Director OHSP, MPH, CIP and Tiffany
More informationHigh Cost Drugs Clinical Coding Standards and Guidance OPCS-4
High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 Clinical Classifications Service Date 6 th March 2014 1 Copyright 2014, Health and Social Care Information Centre. Contents Introduction...
More informationDME REGIONAL Carrier. DME REGIONAL Carrier. service (not separately payable). If other. DME REGIONAL Carrier. DME REGIONAL Carrier
A0021 - A0999 Ambulance Services Local Carrier A4206 - A4209 Medical, Surgical, and Self- Local Carrier if incident to a physician s Administered Injection Supplies A4210 Needle Free Injection Device A4211
More informationTexas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request
Form 1033 September 2017-E Texas Vendor Drug Program Fee-For-Service Medicaid Synagis Authorization Request About Human Respiratory Syncytial Virus (RSV) causes respiratory tract infections and serious
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Clexane Multidose Vial 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Vials containing 300 mg enoxaparin (equivalent to 30,000 IU anti-xa
More informationClinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404
Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this
More informationType: Embedded within the selected substance, indicated when creating the substance.
Overview: Substance Table: Each procedure will include a substance table, either on the main page of the procedure (immediately after selecting the procedure type), embedded elsewhere within a procedure,
More informationSCOPEBOX All-in-One Laparoscopy Unit
LAP 70 1.2 11/2017-E SCOPEBOX All-in-One Laparoscopy Unit The solution for extra-hospital laparoscopic surgery Introduction Laparoscopic surgery has become increasingly popular worldwide over the last
More informationNUH PHARMACY CLINICAL TRIALS. Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014
NUH PHARMACY CLINICAL TRIALS Sheila Hodgson, Lead Pharmacist, Clinical Trials June 30th 2014 Dedicated pharmacy trials staff Lead Pharmacist, Service Co-ordinator Pharmacists: Band 7 and 8a Technicians:
More informationHow do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?
Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental
More informationTranexamic Acid in Joint Replacement Surgery. Donna Berta Blood Conservation Program Coordinator
Tranexamic Acid in Joint Replacement Surgery Donna Berta Blood Conservation Program Coordinator Today s Objectives After this presentation participants will be able to: to describe the basic physiology
More informationInvestor Presenta,on. Dawson Reimer President & COO. Albert D. Friesen, PhD. Chair & CEO
Investor Presenta,on Albert D. Friesen, PhD Chair & CEO Dawson Reimer President & COO March 31, 2015 Disclaimer This presentation is for informational purposes only and should not be considered as an offer
More informationMithra manages today multiple synergistic innovation streams for R&D, manufacturing or commercial partnering
Mithra manages today multiple synergistic innovation streams for R&D, manufacturing or commercial partnering Our mission is to improve every stage of women s life with innovative and accessible pharmaceutical
More informationDesign and Dosage Form. Dr. Deny Susanti
Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:
More informationHistoacryl A revolution in mesh fixation
Histoacryl A revolution in mesh fixation Closure Technologies Histoacryl A revolution in mesh fixation A new indication for a classic product Histoacryl has been used for more than 40 years in operating
More informationDemand Management Plan for Immunoglobulin Use
Demand Management Plan for Immunoglobulin Use BACKGROUND Availability of immunoglobulin to the NHS Therapeutic immunoglobulin, a blood product, is used effectively in the treatment of a wide range of diseases.
More informationHolmium laser prostatectomy
NHS National Institute for Clinical Excellence Holmium laser prostatectomy Understanding NICE guidance information for men considering the procedure, and for the public November 2003 Holmium laser prostatectomy
More informationDivision of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852
May 24, 2012 Division of Dockets Management (HFA 305) U.S. Food and Drug Administration 5630 Fishers Lane Room 1061 Rockville, MD 20852 Re: Comments on Docket #FDA- 2012 D 0148; Draft Guidance for Industry
More informationBIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season
BIOPHARMACEUTICS AND PHARMACOKINETICS Degree in PHARMACY University of Alcalá Academic year 2016/17 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code: 570014 Degree:
More informationFOCUS ON MRSA/SA SSTI ASSAY FAILURE IN PROSTHETIC JOINT. Institute of Microbiology, Lille University Hospital, F Lille, France
JCM Accepted Manuscript Posted Online 16 November 2016 J. Clin. Microbiol. doi:10.1128/jcm.01658-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. FOCUS ON MRSA/SA SSTI ASSAY FAILURE
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED AND RECOMBINANT COAGULATION FACTOR IX PRODUCTS
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 29 June 2000 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED
More informationMIIG INJECTABLE Graft The following languages are included in this packet:
MIIG INJECTABLE Graft 128801-10 The following languages are included in this packet: English (en) Deutsch (de) Nederlands (nl) Français (fr) Español (es) Italiano (it) Português (pt) 中文 - Chinese (sch)
More informationBacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections
Bacteriophage Therapeutics for Patients with Antibiotic-Resistant Infections November 7, 2017 NYSE MKT: APHB Safe Harbor Statement This presentation contains forward-looking statements that involve risks,
More information